Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lobeglitazone + empagliflozin + metformin
- Development stage
- Phase 3
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination drug in development for type 2 diabetes, composed of lobeglitazone (a thiazolidinedione/PARγ agonist), empagliflozin (an SGLT2 inhibitor), and metformin (an AMPK activator). This multi-modal therapy is designed to improve glycemic control by targeting insulin sensitivity, renal glucose reabsorption, and hepatic glucose production through three complementary mechanisms. Developed primarily by Chong Kun Dang Pharmaceutical, this product is undergoing clinical trials to evaluate its pharmacokinetics and safety following oral administration in healthy subjects and in the context of type 2 diabetes mellitus[1][3][7].
- Other names
- Lobeglitazone/D745/D150
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)PRKAB1 (AMPK β1)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on lobeglitazone + empagliflozin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lobeglitazone + empagliflozin + metformin.